Caristo Diagnostics Receives FDA De Novo Authorization for CaRi-Heart AI Platform - HIT Consultant
9/10Caristo Diagnostics received FDA De Novo authorization in July 2026 for its CaRi-Heart AI platform, an AI-powered tool designed to assist cardiac diagnosis. This regulatory milestone marks a significant advancement for AI applications in cardiology diagnostics in the United States.
